Detalhe da pesquisa
1.
Ofatumumab plus HyperCVAD/HD-MA induction leads to high rates of minimal residual disease negativity in patients with newly diagnosed mantle cell lymphoma: Results of a phase 2 study.
Cancer
; 128(8): 1595-1604, 2022 04 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-35157306
2.
Impaired humoral responses to COVID-19 vaccination in patients with lymphoma receiving B-cell-directed therapies.
Blood
; 138(9): 811-814, 2021 09 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34189565
3.
Carfilzomib combined with rituximab, ifosfamide, carboplatin, and etoposide for relapsed or refractory DLBCL.
Blood Adv
; 7(7): 1146-1155, 2023 04 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-36375132
4.
Rituximab in combination with CHOP or fludarabine in low-grade lymphoma.
Semin Oncol
; 29(1 Suppl 2): 36-40, 2002 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-11842387
5.
Bortezomib in combination with pegylated liposomal doxorubicin and thalidomide is an effective steroid independent salvage regimen for patients with relapsed or refractory multiple myeloma: results of a phase II clinical trial.
Leuk Lymphoma
; 50(7): 1096-101, 2009 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-19479618
6.
Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study.
J Clin Oncol
; 24(34): 5343-9, 2006 Dec 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-17088571
7.
Results of a phase 1 clinical trial of thalidomide in combination with fludarabine as initial therapy for patients with treatment-requiring chronic lymphocytic leukemia (CLL).
Blood
; 106(10): 3348-52, 2005 Nov 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-16051743
8.
Rituximab in combination with CHOP or fludarabine in low-grade lymphoma.
Semin Oncol
; 29(1S2): 36-40, 2002 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-28140090